Number of entity's patents that another entity has allegedly infringed.

No definition available.

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of claims dismissed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period from receipt of certification notice until which FDA approval of ANDA will be stayed.

+ References

No definition available.

+ Details

Name:	vvus_PeriodOfStayOfFdaApprovalOfAndaFromReceiptOfCertificationNotice
Namespace Prefix:	vvus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Period prior to expiration notice of the last to expire of patents-in-suit

+ References

No definition available.

+ Details

Name:	vvus_PeriodPriorToExpirationNoticeOfLastToExpireOfPatentsInSuit
Namespace Prefix:	vvus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ThirdParagraphIvCertificationNoticeFromActavisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_SecondParagraphIvCertificationNoticeFromActavisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ParagraphIvCertificationNoticeFromTevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_FederalLeaveToAmendClaimsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_CaliforniaPrejudiceClaimsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_StendraAndaLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_QsymiaAndaLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ActavisLaboratoriesFlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_ShareholderDerivativeLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=vvus_QsymiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LEGAL MATTERS (Details) $ in Millions								12 Months Ended
LEGAL MATTERS (Details) $ in Millions	Jan. 03, 2017	Aug. 05, 2015 item	Jul. 07, 2015 item	Jun. 18, 2015 item	Mar. 05, 2015	Jan. 21, 2015 item	Mar. 27, 2014 USD ($)	Dec. 31, 2014
Third Paragraph IV Certification Notice from Actavis Member
LEGAL MATTERS
Number of patents-in-suit			2
Gain Contingency, Patents Allegedly Infringed upon, Number			2
Second Paragraph IV Certification Notice from Actavis Member
LEGAL MATTERS
Number of patents-in-suit						2
Gain Contingency, Patents Allegedly Infringed upon, Number						2
Paragraph IV Certification Notice from Teva Pharmaceuticals Member
LEGAL MATTERS
Number of patents-in-suit		2
Period from receipt of certification notice until which FDA approval of ANDA will be stayed					30 months
Period of stay of FDA approval of ANDA from receipt of certification notice					30 months
Gain Contingency, Patents Allegedly Infringed upon, Number		2
Federal Leave To Amend Claims Member
LEGAL MATTERS
Loss Contingency, Claims Dismissed, Number				2
California Prejudice Claims Member
LEGAL MATTERS
Loss Contingency, Claims Dismissed, Number				7
STENDRA ANDA Litigation member
LEGAL MATTERS
Period prior to expiration notice of the last to expire of patents-in-suit	180 days
Qsymia ANDA Litigation \| Actavis Laboratories FL
LEGAL MATTERS
Period from receipt of certification notice until which FDA approval of ANDA will be stayed								30 months
Period of stay of FDA approval of ANDA from receipt of certification notice								30 months
Shareholder derivative lawsuit \| Minimum \| Qsymia
LEGAL MATTERS
Amount of damages sought \| $							$ 2.8